Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Mark C GenoveseRoy FleischmannAlan KivitzEun-Bong LeeHubert van HoogstratenToshio KimuraGregory St JohnErin K ManganGerd R BurmesterPublished in: Arthritis research & therapy (2020)
ClinicalTrials.gov NCT01061736, registered on February 03, 2010; ClinicalTrials.gov NCT01709578, registered on October 18, 2012; ClinicalTrials.gov NCT02332590, registered on January 07, 2015.